By Allison Proffitt 

June 22, 2022 | uMotif and ClinOne have announced a partnership to provide integrated electronic clinical outcomes assessments (eCOA) and electronic informed consent (eConsent) technology. While currently the two solutions remain distinct, Andrea Valente, CEO at ClinOne, presented the news as the first step on an ongoing partnership to, “increase usage across all trials and all sites to ensure everyone benefits from simple, reliable technology that people find a joy to use.” 

uMotif’s eCOA / ePRO (patient reported outcomes) and engagement platform improves participant experience, transforming the reliability of patient-reported and site-based endpoint data used for new drug approval decisions. eConsent on ClinOne’s adaptive experience platform reduces the risk of consent-related errors and enables more informed participation decisions. 

The two solutions already share a common data layer, “which is the most important and foundational aspect when considering a unified, user-centric solution to solve our customers toughest issues,” Valente told Clinical Research News. “Our product development teams are well underway, working collaboratively, to create a unified single experience that further elevates the experience,” she added.

Both products will still be available independently, but the companies hope that using the tools together will simplify the user experience for sites and patients while providing greater accountability and efficiency for sponsor and CRO study teams, Valente said. “As our mutual customers continue to increasingly source eConsent, eCOA and ePRO solutions (albeit from multiple providers), we are proud to do the behind-the-scenes work that makes it easier for them to use ClinOne and uMotif solutions together as one.”

Inspired by collaboration within pharma and biotech, Valente said both ClinOne and uMotif, “believe it is time for technology providers to do the same.” 

Today many patients and clinical research coordinators struggle to navigate a changing constellation of systems, apps, and sensors for each individual protocol, the companies wrote in their announcement. Both patient and site participants consistently rank multiple and duplicative logins, trainings, and data entry along with inconsistent user experiences as top challenges to sustain clinical trial participation.  

The two companies built their platforms with extensibility and intuitive user experiences at their core, they say. Together they feature the inherent flexibility to support fully decentralized trials (DCT), traditional site-based studies, and hybrid designs of any scale or therapeutic area complexity. Together they will be cost-accessible, fast to deploy, and easy for participants to use on their own familiar mobile devices. 

“As our partnership evolves,” Valente adds, “we will work together through our joint governance framework to deepen our product offering and ensure that we are tightly aligned and delivering maximum value to those we serve.”